Video

Unmet Needs and Future Perspectives in Multiple Myeloma Care

Author(s):

Sagar Lonial, MD,Amrita Krishnan, MD

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Related Videos
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Syed Abbas Ali, MBBS
4 experts are featured in this series.
Related Content
Multiple Myeloma | stock.adobe.com
January 19th 2025

Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple Myeloma | Image Credit: © Maris– stock.adobe.com
January 13th 2025

Isatuximab Plus Pomalidomide and Dexamethasone Receives Approval in China for Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Subcutaneous Isatuximab Plus Pd in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com
January 9th 2025

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

Multiple Myeloma | stock.adobe.com
January 6th 2025

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma